[Piet de Somer, the University of Leuven and the Belgium poliovaccine in 1956-57].
In the years following WW II, all 'Western' countries were struck by recurrent epidemics of infantile paralysis (poliomyelitis). In the early 1950s, a vaccine developed by Jonas Salk in Pittsburgh, became available in the U.S. and Canada. In 1953-54 central virology laboratories in Sweden, Denmark and France were already well advanced in setting up local production lines of the vaccine. At that point in time, the Catholic University of Leuven, on the initiative of the young microbiology professor, Piet De Somer, and in collaboration with the pharmaceutical concern R.I.T. (Recherches et Industries Thérapeutiques, Genval, Belgium), erected a new, multidisciplinary medical research institute, the Rega Institute. One of the research units to be headed by De Somer was destined to introduce the relatively new discipline of virology. As a test case, De Somer decided to venture on developing a production line of the Salk vaccine. In less than one year's time, the project was successful, such that Belgium became one of the first European countries to be self-supporting for its vaccine supply and to be able to initiate a large-scale vaccination campaign. The planning, preparation and execution of the project was accompanied by an extensive correspondence of De Somer with experts and other concerned parties in Belgium and abroad. This correspondence has been preserved and allows for a detailed reconstruction of the remarkable achievement.